moneyheap
KTTA · Analysis updated Nov 4, 2026, 2:39 AM ET
Why is Pasithea Therapeutics Corp. (KTTA) stock moving?
Pasithea Therapeutics (KTTA) experienced a major catalyst on November 3, 2026, when the FDA cleared its Investigational New Drug (IND) application to advance lead candidate PAS-004 into a Phase 2 trial for neurofibromatosis type 1 (NF1)-associated cutaneous neurofibromas. This regulatory green light follows encouraging Phase 1 safety and pharmacokinetic data presented at the ESMO Congress in late October. In response to the IND milestone, KTTA surged on November 3 from an open of $0.365 to close at $0.530 (+44%), accompanied by an extraordinary volume spike to 42,935 trades compared to typical daily activity under 2,000 trades. While the expansion into Phase 2 represents a major strategic and clinical step forward, the company remains clinical-stage and vulnerable to high microcap biotech volatility as it advances into clinical execution and scheduled investor events.
News behind the analysis
- Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)The FDA cleared an Investigational New Drug application for a randomized, placebo-controlled Phase 2 trial of lead oral MEK inhibitor PAS-004 in NF1-associated cutaneous neurofibromas.
- Pasithea gets FDA IND clearance for PAS-004 in skin tumor conditionPasithea announced regulatory clearance to advance PAS-004 into Phase 2 development for adult cutaneous neurofibromas under the FDA Division of Dermatology and Dentistry.
- Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026Key opinion leaders will join company management in a virtual event to discuss the treatment landscape and unmet needs for NF1-associated neurofibromas.
- Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026Phase 1 clinical data presented at ESMO demonstrated favorable safety, flat pharmacokinetics, and prolonged stable disease in heavily pre-treated solid tumor patients.
- Pasithea Therapeutics (KTTA) Market Move on Phase 2 IND ClearanceKTTA experienced a sharp surge in trading volume and momentum following the FDA IND clearance announcement for PAS-004.